| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| 2861- | FIS, | The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2842- | FIS, | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 2642- | Flav, | QC, | Api, | KAE, | MCT | In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 6979- | Form, | Pharmacokinetics and Bioavailability of the Isoflavones Formononetin and Ononin and Their in Vitro Absorption in Ussing Chamber and Caco-2 Cell Models |
| - | in-vitro, | Colon, | Caco-2 |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6983- | Form, | Formononetin enhances angiogenesis in diabetic wounds by inhibiting ferroptosis through suppression of mtROS-mediated xCT/GPX4 upregulation |
| - | vitro+vivo, | Nor, | HUVECs | - | vitro+vivo, | Diabetic, | NA |
| 6996- | Form, | MET, | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro |
| - | in-vitro, | BC, | MCF7 |
| 6963- | Form, | Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 6967- | Form, | BTZ, | Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model |
| - | in-vivo, | Melanoma, | U266 | - | in-vivo, | Melanoma, | RPMI-8226 |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
| 6972- | Form, | PacT, | Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy |
| - | in-vivo, | BC, | MDA-MB-231 |
| 6973- | Form, | Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways |
| - | Human, | BC, | NA |
| 6974- | Form, | Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein |
| - | in-vitro, | Cerv, | HeLa |
| 6975- | Form, | Formononetin inhibits colorectal cancer via the miR-490-3p/ABCC2 axis and synergizes with 5-fluorouracil: mechanistic insights and therapeutic implications |
| - | vitro+vivo, | CRC, | NA |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | NA, | APL, | APL NB4 | - | vitro+vivo, | NA, | NA |
| 7018- | Fuc, | Absorption Study of Mozuku Fucoidan in Japanese Volunteers |
| - | Trial, | Nor, | NA |
| 7022- | Fuc, | Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling |
| - | in-vitro, | Colon, | HT29 |
| 7001- | Fuc, | Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer |
| - | Trial, | CRC, | NA |
| 7005- | Fuc, | Fucoidan and cancer: a multifunctional molecule with anti-tumor potential |
| - | Review, | Var, | NA |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 7043- | GA, | Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase |
| - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | A549 |
| 7044- | GA, | QC, | Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity |
| - | in-vitro, | BC, | MCF7 |
| 7032- | GA, | Cisplatin, | Gallic acid: a polyphenolic compound potentiates the therapeutic efficacy of cisplatin in human breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 7033- | GA, | OL, | Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line |
| - | in-vitro, | OS, | U2OS |
| 7027- | GA, | Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans |
| - | Human, | Nor, | NA |
| 7069- | GABA, | United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) |
| - | Review, | Nor, | NA |
| 7076- | GABA, | Anti-hypertensive effect of gamma-aminobutyric acid (GABA)-rich Chlorella on high-normal blood pressure and borderline hypertension in placebo-controlled double blind study |
| - | Trial, | Nor, | NA |
| 7080- | GABA, | The Effect of Oral GABA on the Nervous System: Potential for Therapeutic Intervention |
| - | Review, | AD, | NA |
| 7081- | GABA, | Exploring the Therapeutic Potential of Gamma-Aminobutyric Acid in Stress and Depressive Disorders through the Gut–Brain Axis |
| - | Review, | AD, | NA |
| 7082- | GABA, | Contributions of Gamma-Aminobutyric Acid (GABA) Produced by Lactic Acid Bacteria on Food Quality and Human Health: Current Applications and Future Prospects |
| - | Review, | AD, | NA |
| 7051- | Gallo, | MET, | Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 7053- | Gallo, | Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Bxpc-3 |
| 5152- | GamB, | Gambogic Acid as a Candidate for Cancer Therapy: A Review |
| - | Review, | Var, | NA |
| 5148- | GamB, | Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics |
| - | Review, | Var, | NA |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1955- | GamB, | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 1960- | GamB, | Vem, | Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
| 1961- | GamB, | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1962- | GamB, | HCQ, | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
| - | in-vitro, | PC, | NA |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid